Cel-Sci Gets Taiwan Approval For Trials Of Drug For Head, Neck Cancer
This article was originally published in PharmAsia News
Executive SummaryAustria's Cel-Sci has received approved from Taiwan authorities for clinical trials of a treatment for head and neck cancer
You may also be interested in...
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
The coronavirus COVID-19 outbreak poses a “limited immediate risk” to European production and supplies of off-patent drugs, according to industry association Medicines for Europe. However, if the situation continues for an extended period an “important impact” cannot be ruled out.